Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $16.6667.

A number of analysts recently issued reports on ALT shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target (down from $25.00) on shares of Altimmune in a report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. B. Riley Financial decreased their target price on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Citizens Jmp lowered their target price on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Finally, Truist Financial started coverage on Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price target on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. increased its holdings in Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after buying an additional 1,928 shares during the period. PKS Advisory Services LLC purchased a new stake in Altimmune during the fourth quarter worth $55,000. Concurrent Investment Advisors LLC lifted its holdings in Altimmune by 10.4% during the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after buying an additional 2,500 shares during the period. Kingswood Wealth Advisors LLC boosted its position in Altimmune by 133.8% during the 4th quarter. Kingswood Wealth Advisors LLC now owns 36,000 shares of the company’s stock valued at $130,000 after acquiring an additional 20,600 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC boosted its position in Altimmune by 7.3% during the 4th quarter. Summit Financial Wealth Advisors LLC now owns 103,288 shares of the company’s stock valued at $373,000 after acquiring an additional 7,000 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Trading Up 1.1%

Shares of ALT opened at $2.64 on Tuesday. The firm has a market capitalization of $513.40 million, a price-to-earnings ratio of -2.84 and a beta of 0.21. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56. Altimmune has a 1-year low of $2.56 and a 1-year high of $7.73. The company has a 50-day moving average of $3.01 and a 200 day moving average of $3.89.

Altimmune (NASDAQ:ALT) last issued its earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. On average, research analysts expect that Altimmune will post -0.69 EPS for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.